AMP-Led Project Compares Bioinformatics Pipelines for Analyzing Cancer Panel Data

ROTTERDAM, Netherlands (GenomeWeb) – Many clinical laboratories now routinely run cancer sequencing panels to identify potentially actionable mutations in patient tumor samples, but there is no gold standard yet for next-generation sequencing data analysis and interpretation. As a result, reports of clinically actionable variants may differ, even if the underlying sequence data is identical.